A Phase 2 interventional study of Psilocybin in Major Depressive Disorder, sponsored by COMPASS Pathways. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing psilocybin in Depressive Disorder, Major — 11 open to participants now, 16 under way, 4 of them phase 3. Psilocybin · Depressive Disorder, Major.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 25 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 16th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →11 of the 31 studies testing psilocybin in Depressive Disorder, Major are open now, in 7 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–75
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University Medical Center Groningen · Sites in Czechia, Denmark, Netherlands and 1 more country
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 6 started in 2023.
This study's enrollment of 102 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 35 across the 31 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies testing psilocybin in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT05947383Sunstone MedicalTwo Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | 2027-04-30 |
| NCT07479550Stanford UniversityStudy of Psilocybin Under Anesthesia Controlled by EEG | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
This is a phase II, multi-centre, randomised, double-blind, controlled study. The study population will include participants aged ≥18 years with recurrent Major Depressive Disorder (MDD) with up to four prior treatment failures of an antidepressant in their current depressive episode.
Overall, 102 participants will be randomised in a 1:1:1 ratio to receive COMP360 25 mg, COMP360 10mg or COMP360 1 mg.
In this study the aim is to investigate the safety and tolerability of COMP360, administered with psychological support, in adult participants with MDD with one prior treatment failure. In addition, pharmacokinetics and efficacy of COMP360 will be investigated.
The study will last up to 16 weeks including a three- to ten-week Screening Period and a six-week follow-up from investigational product (IP) administration.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg COMP360 Psilocybin
Drug: Psilocybin
10 mg COMP360 Psilocybin
Drug: Psilocybin
1 mg COMP360 Psilocybin
Drug: Psilocybin
COMP360 Psilocybin administered under supportive conditions
Also known as: COMP360
Safety and tolerability of COMP360 Psilocybin
Proportion of patients with adverse events (AEs)
Time frame: Up to Week 6
Pharmacokinetics of COMP360 Psilocybin
Plasma concentrations of psilocybin, psilocin, 4-hydroxyindoleacetic acid (4-HIAA) and psilocin-O-glucuronide post-COMP360 administration on Day 1
Time frame: Day 1
Change from baseline in MADRS total score at Week 3 and Week 6 for COMP360 25 mg versus COMP360 1 mg
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity
Time frame: Week 3 and Week 6
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Sep 2025, 32 months after the start.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 32 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
COMPASS Pathways